Literature DB >> 21993476

Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients.

Harriet Corvol1, Julie Beucher, Pierre-Yves Boëlle, Pierre-François Busson, Céline Muselet-Charlier, Annick Clement, Felix Ratjen, Hartmut Grasemann, Judith Laki, Colin N A Palmer, J Stuart Elborn, Anil Mehta.   

Abstract

BACKGROUND: The clinical course of cystic fibrosis (CF) lung disease varies between patients bearing identical CFTR mutations. This suggests that additional genetic modifiers may contribute to the pulmonary phenotype. The highly conserved ancestral haplotype 8.1 (8.1AH), carried by up to one quarter of Caucasians, comprises linked gene polymorphisms on chromosome 6 that play a key role in the inflammatory response: LTA +252A/G; TNF -308G/A, HSP70-2 +1267A/G and RAGE -429T/C. As inflammation is a key component inducing CF lung damage, we investigated whether the 8.1AH represents a lung function modifier in CF.
METHODS: We analyzed the lung function of 404 European CF patients from France (n=230), Germany (n=95) and UK (n=79). FEV(1) differences between 8.1AH carriers and non-carriers were calculated in each country and pooled using a random effects model.
RESULTS: The frequency of 8.1AH carriers was similar between French (22%), German (29%) and UK (27%) patients. We found that 8.1AH carriers had significantly lower FEV(1), adjusted for age classes and countries (P<0.04, mean FEV(1) difference -6.4% CI95% [-12.4%, -0.5%]). No difference was observed with respect to BMI Z-scores and chronic colonization with P. aeruginosa.
CONCLUSIONS: These findings support the concept that 8.1AH is an important genetic modifier of lung disease in CF. To conclude, multiple linked genes outside the CF locus might explain some of the variability in lung phenotype.
Copyright © 2011 European Cystic Fibrosis Society. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21993476     DOI: 10.1016/j.jcf.2011.09.006

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  11 in total

1.  Receptor for advanced glycation end-products and environmental exposure related obstructive airways disease: a systematic review.

Authors:  Syed H Haider; Assad Oskuei; George Crowley; Sophia Kwon; Rachel Lam; Jessica Riggs; Mena Mikhail; Angela Talusan; Arul Veerappan; James S Kim; Erin J Caraher; Anna Nolan
Journal:  Eur Respir Rev       Date:  2019-03-27

2.  Human leukocyte antigen (HLA) haplotype matching in unrelated single HLA allele mismatch bone marrow transplantation.

Authors:  Akihisa Kawajiri; Takakazu Kawase; Hidenori Tanaka; Takahiro Fukuda; Junichi Mukae; Yukiyasu Ozawa; Tetsuya Eto; Naoyuki Uchida; Takehiko Mori; Takashi Ashida; Tadakazu Kondo; Makoto Onizuka; Tatsuo Ichinohe; Yoshiko Atsuta; Satoko Morishima; Junya Kanda
Journal:  Bone Marrow Transplant       Date:  2022-01-21       Impact factor: 5.174

3.  Receptor for advanced glycation end-products and World Trade Center particulate induced lung function loss: A case-cohort study and murine model of acute particulate exposure.

Authors:  Erin J Caraher; Sophia Kwon; Syed H Haider; George Crowley; Audrey Lee; Minah Ebrahim; Liqun Zhang; Lung-Chi Chen; Terry Gordon; Mengling Liu; David J Prezant; Ann Marie Schmidt; Anna Nolan
Journal:  PLoS One       Date:  2017-09-19       Impact factor: 3.240

4.  AGER -429T/C is associated with an increased lung disease severity in cystic fibrosis.

Authors:  Julie Beucher; Pierre-Yves Boëlle; Pierre-François Busson; Céline Muselet-Charlier; Annick Clement; Harriet Corvol
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

5.  TNF gene polymorphisms in cystic fibrosis patients: contribution to the disease progression.

Authors:  Galina Shmarina; Alexander Pukhalsky; Nika Petrova; Ekaterina Zakharova; Lucine Avakian; Nikolai Kapranov; Vladimir Alioshkin
Journal:  J Transl Med       Date:  2013-01-23       Impact factor: 5.531

6.  Reference percentiles for FEV(1) and BMI in European children and adults with cystic fibrosis.

Authors:  Pierre-Yves Boëlle; Laura Viviani; Pierre-Francois Busson; Hanne V Olesen; Sophie Ravilly; Martin Stern; Baroukh M Assael; Celeste Barreto; Pavel Drevinek; Muriel Thomas; Uros Krivec; Meir Mei-Zahav; Jean-François Vibert; Annick Clement; Anil Mehta; Harriet Corvol
Journal:  Orphanet J Rare Dis       Date:  2012-09-07       Impact factor: 4.123

7.  Genetic influences on cystic fibrosis lung disease severity.

Authors:  Colleen A Weiler; Mitchell L Drumm
Journal:  Front Pharmacol       Date:  2013-04-23       Impact factor: 5.810

8.  Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis.

Authors:  Harriet Corvol; Scott M Blackman; Pierre-Yves Boëlle; Paul J Gallins; Rhonda G Pace; Jaclyn R Stonebraker; Frank J Accurso; Annick Clement; Joseph M Collaco; Hong Dang; Anthony T Dang; Arianna Franca; Jiafen Gong; Loic Guillot; Katherine Keenan; Weili Li; Fan Lin; Michael V Patrone; Karen S Raraigh; Lei Sun; Yi-Hui Zhou; Wanda K O'Neal; Marci K Sontag; Hara Levy; Peter R Durie; Johanna M Rommens; Mitchell L Drumm; Fred A Wright; Lisa J Strug; Garry R Cutting; Michael R Knowles
Journal:  Nat Commun       Date:  2015-09-29       Impact factor: 14.919

Review 9.  Disease-modifying genes and monogenic disorders: experience in cystic fibrosis.

Authors:  Sabina Gallati
Journal:  Appl Clin Genet       Date:  2014-07-10

10.  Inheritance of the 8.1 ancestral haplotype in recurrent pregnancy loss.

Authors:  Astrid M Kolte; Henriette S Nielsen; Rudi Steffensen; Bernard Crespi; Ole B Christiansen
Journal:  Evol Med Public Health       Date:  2015-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.